
Company Website:
http://www.BSDMedical.com
SALT LAKE CITY -- (Business Wire)
BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, announced today that the Company has sold a MicroThermX®
Microwave Ablation (MicroThermX®) system and antennas to
P.J.V. Micromedics, P.C. (Micromedics). Micromedics is BSD's exclusive
distributor in Greece for the MicroThermX®. Micromedics is a
leading, medical, specialty distributor in Greece and has established
relationships with key opinion leaders in the interventional radiology
field. Their extensive sales network provides a dedicated team of market
specialists presenting the advantages of the MicroThermX® to
hospitals throughout Greece. Micromedics sells strategically adjacent
products to the same clinicians targeted for the MicroThermX®.
Greece has a very progressive medical market. There are a large number
of practicing physicians working in Greece. Imports constitute
approximately 93% of the medical device market. High value medical
equipment is imported in both the public and private healthcare sectors.
About the MicroThermX® Microwave Ablation
System
The MicroThermX® is a compact, mobile, state-of-the-art,
proprietary system that includes a microwave generator,
single-patient-use disposable antennas and a thermistor-based
temperature monitoring system. The innovative design of the MicroThermX®
is the first of its kind that allows delivery of higher power
levels using a single generator. The MicroThermX® utilizes
innovative synchronous phased array technology that was developed and
patented by BSD to provide larger and more uniform zones of ablation
during a single procedure. The MicroThermX® introduces into
the Company’s product line innovative, high-end disposables (SynchroWave
antennas) that are used in each ablation treatment and will provide a
significant ongoing revenue stream. The soft tissue ablation world
market potential is estimated to exceed $2.3 billion. The U.S. Food and
Drug Administration (FDA) has granted the Company a 510(k) clearance to
market the MicroThermX® for ablation of soft tissue. BSD has
also received CE Marking for the MicroThermX® System, which
allows BSD to market the MicroThermX® in Europe. CE Marking
is also recognized in many countries outside of the EU, providing BSD
the ability to market the MicroThermX® to a number of
international markets.
About BSD Medical Corporation
BSD Medical Corporation develops, manufactures, markets and services
systems to treat cancer and benign diseases using heat therapy, which is
delivered using focused radiofrequency (RF) and microwave energy. BSD’s
product lines include both hyperthermia and ablation treatment systems.
BSD’s hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat
certain tumors with heat (hyperthermia) while increasing the
effectiveness of other therapies such as radiation therapy. BSD’s
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft
tissue. The Company has developed extensive intellectual property,
multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States,
Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.
Statements contained in this press release that are not historical facts
are forward-looking statements, as defined in the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
subject to risks and uncertainties detailed in the Company's filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date on which such statements are made,
and the Company undertakes no obligation to update such statements to
reflect events or circumstances arising after such date.
Contacts:
BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
Fax:
801-972-5930
investor@bsdmc.com
Source: BSD Medical Corporation
© 2018 Canjex Publishing Ltd. All rights reserved.